China's National Medical Products Administration accepted Yantai Dongcheng Pharmaceutical's (SHE:002675) marketing authorization application for bemiparin sodium injection, according to a Shenzhen bourse filing on Thursday.
The drug is used to prevent blood clotting during hemodialysis and thromboembolic diseases during surgery.